首页>
外国专利>
Compositions for treating gefitlnib resistant cancers having egfr t790m mutation using irreversible egfr inhibitors
Compositions for treating gefitlnib resistant cancers having egfr t790m mutation using irreversible egfr inhibitors
展开▼
机译:使用不可逆的egfr抑制剂治疗具有egfr t790m突变的吉非替尼耐药性癌症的组合物
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
展开▼